The National Institutes of Health (NIH) is shifting its vaccine research strategy, moving away from mRNA technology and investing in a traditional approach known as whole-virus vaccines. The decision, announced by the Trump administration earlier this month, redirects $500 million from mRNA studies toward a program branded “Generation Gold Standard.”
NIH Director Dr. Jay Bhattacharya described the effort as a “paradigm shift” that could extend protection beyond strain-specific limits, particularly against influenza. The initiative aims to modernize conventional vaccine platforms to prepare for future viral threats.
But many infectious disease specialists argue the move is a step backward.
“We’ve had inactivated whole-virus vaccines for a very long time,” said Dr. James Campbell, vice chair of the American Academy of Pediatrics Committee on Infectious Diseases. “It’s not innovative at all.”
Whole-virus vaccines, first pioneered by Louis Pasteur in the 19th century, use either killed or weakened viruses to trigger an immune response. Unlike newer methods that target specific viral proteins, whole-virus vaccines expose the immune system to most viral components.
Dr. Paul Offit, director of the Vaccine Education Center at the Children’s Hospital of Philadelphia, explained: “You take the virus, grow it, purify it, and kill it with an inactivating agent. That’s a whole-killed viral vaccine.”
Limits of Whole-Virus Vaccines
Experts note that modern vaccines often achieve stronger protection with fewer components. For instance, the hepatitis B vaccine relies on a single surface antigen yet provides nearly complete protection.
Similarly, mRNA vaccines developed for COVID-19—targeting only the spike protein—outperformed whole-virus versions used abroad. A study from Singapore found whole-virus COVID-19 vaccines left recipients nearly twice as likely to be infected compared with mRNA vaccines.
Campbell cautioned that whole-virus platforms can also cause harm. He cited the failed 1960s respiratory syncytial virus (RSV) vaccine trial, in which children who received a killed whole-virus version developed more severe illness. That setback delayed RSV vaccine development for decades.
Today, whole-virus vaccines remain in use for rabies, hepatitis A, and seasonal flu. However, experts stress that their value depends on the pathogen.
A Universal Flu Vaccine?
The Department of Health and Human Services argues the new platform could advance the long-sought universal flu vaccine, capable of providing long-term protection against multiple strains. HHS press secretary Emily Hilliard said the program represents a “critical step in restoring strategic focus” to pandemic preparedness.
The platform uses beta-propiolactone (BPL), a chemical long used to inactivate viruses for vaccine production.
Still, Campbell questioned whether focusing narrowly on whole-virus technology will deliver breakthroughs:
“Putting all our eggs in one basket—especially one that’s an old technology that has failed to produce a universal flu vaccine before—is not really moving the field along.”
Concerns Over Abandoning mRNA Research
Critics warn that cutting mRNA funding could undermine preparedness for future pandemics. Unlike whole-virus vaccines, mRNA vaccines can be designed and manufactured quickly without growing live viruses.
“If there’s a bird flu pandemic, we will be less prepared,” Offit said. “mRNA has a much shorter production cycle.”
Virologist Angela Rasmussen added that scaling up whole-virus vaccine production could take a year, compared with weeks for mRNA.
The Scientific Bottom Line
Experts emphasize that vaccine development should not be dictated by politics.
“The devil is in the details,” Campbell said. “We need to compare platforms through science, not sweeping statements.”
In vaccinology, he added, progress comes from testing multiple approaches and allowing evidence—not directives—to determine the best tools for future outbreaks.
